Cara Cassino
Keine laufenden Positionen mehr
Vermögen: - $ am 31.03.2024
Profil
Cara Cassino worked as an Executive Medical Director at Boehringer Ingelheim Pharmaceuticals, Inc. from 2001 to 2007.
She then worked as the Group VP-Pulmonary Vascular & Rare Diseases at Pfizer Inc. from 2008 to 2013.
In 2014, she was the Senior Vice President at Forest Laboratories, Inc. From 2015 to 2022, she worked as the Chief Medical Officer & EVP-Research & Development at ContraFect Corp.
Prior to her business career, she was a Member of the Pulmonary & Critical Care Medicine Division at New York University School of Medicine.
She earned her doctorate from New York University School of Medicine and her undergraduate degree from NYU College of Dentistry.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CONTRAFECT CORP.
-.--% | 06.09.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Ehemalige bekannte Positionen von Cara Cassino
| Unternehmen | Position | Ende |
|---|---|---|
| CONTRAFECT CORPORATION | Chief Tech/Sci/R&D Officer | 14.08.2022 |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | 01.09.2015 |
| PFIZER, INC. | Corporate Officer/Principal | 01.01.2013 |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Chief Tech/Sci/R&D Officer | 01.01.2007 |
| New York University School of Medicine | Corporate Officer/Principal | - |
Ausbildung von Cara Cassino
| NYU College of Dentistry | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| CONTRAFECT CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
